A doubly robust approach for cost–effectiveness estimation from observational data

Estimation of common cost–effectiveness measures, including the incremental cost–effectiveness ratio and the net monetary benefit, is complicated by the need to account for informative censoring and inherent skewness of the data. In addition, since the two components of these measures, medical costs and survival are often collected from observational claims data, one must account for potential confounders. We propose a novel doubly robust, unbiased estimator for cost–effectiveness based on propensity scores that allow the incorporation of cost history and time-varying covariates. Further, we use an ensemble machine learning approach to obtain improved predictions from parametric and non-parametric cost and propensity score models. Our simulation studies demonstrate that the proposed doubly robust approach performs well even under mis-specification of either the propensity score model or the outcome model. We apply our approach to a cost–effectiveness analysis of two competing lung cancer surveillance proc...